| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it has begun opening clinical trial sites in the European Union (EU) and may begin screening participants for the Phase 3 ALPHA-ORBIT trial of navenibart, an investigational monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of hereditary angioedema (HAE) with the potential for dosing every 3 and 6 months.
Astria is enrolling the ongoing ALPHA-ORBIT trial with clinical trial sites open and accepting HAE patients across the United States, Europe, United Kingdom, Canada, Hong Kong, South Africa, Japan, North Macedonia, and Israel. Approval for the ALPHA-ORBIT trial from the European Medicines Agency (EMA) sanctions the activation of an anticipated 32 sites in 10 EU countries: Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, and Spain.
Posted In: ATXS
